Status:
COMPLETED
A Study of LY317615 in Patients With Brain Tumors
Lead Sponsor:
Eli Lilly and Company
Conditions:
Malignant Glioma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
1. The safety of LY317615 and any side effects that might be associated with the drug. 2. Whether LY317615, can help patients with brain tumors.
Eligibility Criteria
Inclusion
- You must be at least 18 years old
- You must have been diagnosed with a recurrent brain tumor by MRI or CT scan
- You must be able to swallow the LY317615 tablets
Exclusion
- You are a woman who is pregnant or breastfeeding
- In view of your doctor, you have significant heart, liver, kidney, or psychiatric disease
Key Trial Info
Start Date :
October 1 2002
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00190723
Start Date
October 1 2002
End Date
December 1 2006
Last Update
January 26 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Bethesda, Maryland, United States, 20892